UniQure's AMT-130 Huntington's gene therapy readout expected
核心洞察
uniQure has guided that a four-year update from its Phase 1/2 AMT-130 study in Huntington's disease (搜索) is expected by September 30, 2026.
The company submitted a biologics license application for AMT-130 earlier in September 2026 based on three-year clinical data compared with an external control.
AMT-130 is designed to reduce production of the mutant huntingtin protein (搜索), and the four-year readout will add a further year of efficacy and safety follow-up.
uniQure has guided that a four-year data update from its Phase 1/2 study of AMT-130 in Huntington's disease (搜索) is expected by September 30, 2026. The readout follows a biologics license application submitted earlier in September 2026 that relied on three-year clinical data compared with an external control group.
AMT-130 is designed to reduce production of the mutant huntingtin protein (搜索), which is central to the pathophysiology of Huntington's disease (搜索). The four-year dataset will add a fourth year of efficacy and safety observations and will also test the robustness of the external-control comparisons underpinning the BLA.
The program is the main focus of uniQure's pipeline, and the company is a mid-cap biotechnology company whose shares trade on Nasdaq. Any subsequent regulatory feedback on the filing, alongside the durability and safety trends in the four-year update, is the near-term checkpoint for the program.
Source: ad-hoc-news.de